Job Trends
Labor Market Reports
Among those who connected salary increases to swapping out employers, 75% saw pay rise by at least 6%, and the most often cited increase was 10%, according to the just-released BioSpace salary report.
BioSpace‘s 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026.
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Now Hiring
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Looking for a clinical job? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Last month, for the first time in nearly four years, average job postings live on BioSpace did not decline year over year. In another encouraging sign, the number of biopharmas letting employees go fell.
Career Advice
Recruiters can play a significant role in biopharma professionals getting hired, especially in an employer-driven job market. However, when working with them, candidates need to avoid making six key mistakes, from waiting too long to ask for help to prematurely contacting hiring companies.
THE LATEST
The scenery will continue to change for GlaxoSmithKline as the company’s planned demerger looms on the horizon. On Monday, GSK gave a glimpse of where the companies will call home post-split.
It was a busy week for clinical trial news. Here’s a look.
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.
Centessa Pharmaceuticals and genomics testing firm Sophia Genetics have both announced plans to expand their real estate footprints in Boston.
The drug, called RGX-314, is a possible one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases.
Philip Dormitzer explained that there are plenty of reasons to be excited about the prophylactic and therapeutic potential of mRNA.